{"id":"bcg-vaccine-freeze-dried","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Local reaction at injection site (erythema, induration)"},{"rate":"5-15","effect":"Fever"},{"rate":"1-5","effect":"Lymphadenitis (regional lymph node enlargement)"},{"rate":"<0.1","effect":"Disseminated BCG infection (rare, immunocompromised)"}]},"_chembl":{"chemblId":"CHEMBL2108905","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG (Bacillus Calmette-Guérin) is a live attenuated strain of Mycobacterium bovis that primes both cellular and innate immune responses against tuberculosis. The vaccine induces CD4+ and CD8+ T-cell responses and activates macrophages to control intracellular mycobacterial infection. It also provides non-specific immunological benefits through trained immunity mechanisms.","oneSentence":"BCG vaccine stimulates the immune system to recognize and attack Mycobacterium tuberculosis by activating T-cell and macrophage-mediated immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:41.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis prevention (primary indication)"},{"name":"Bladder cancer (intravesical BCG therapy)"}]},"trialDetails":[{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48},{"nctId":"NCT06997367","phase":"PHASE2","title":"Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)","status":"RECRUITING","sponsor":"Bharat Biotech International Limited","startDate":"2025-03-01","conditions":"Tuberculosis (TB)","enrollment":164},{"nctId":"NCT04327206","phase":"PHASE3","title":"BCG Vaccination to Protect Healthcare Workers Against COVID-19","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2020-03-30","conditions":"Coronavirus Disease 2019 (COVID-19), Respiratory Illness, Corona Virus Infection","enrollment":6828},{"nctId":"NCT04899765","phase":"PHASE4","title":"Measles and BCG Vaccines for Mother and Child","status":"RECRUITING","sponsor":"Bandim Health Project","startDate":"2021-05-20","conditions":"Vaccine Preventable Disease, Measles, Mother-Infant Interaction","enrollment":2400},{"nctId":"NCT05284812","phase":"PHASE2","title":"A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"SUSPENDED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-02-10","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT04475302","phase":"PHASE3","title":"BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2020-07-01","conditions":"COVID","enrollment":2175},{"nctId":"NCT04435379","phase":"PHASE3","title":"Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2020-06-18","conditions":"Infection, Respiratory Tract","enrollment":2038},{"nctId":"NCT04414267","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent COVID-19","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2020-05-26","conditions":"COVID-19, Virus Diseases, Corona Virus Infection","enrollment":301},{"nctId":"NCT04632537","phase":"PHASE3","title":"BCG Vaccination to Prevent COVID-19","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2020-12-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04387409","phase":"PHASE3","title":"Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Serum Life Science Europe GmbH","startDate":"2020-05-25","conditions":"Infection, Respiratory Tract","enrollment":59},{"nctId":"NCT02389322","phase":"PHASE2","title":"Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2015-03","conditions":"Tuberculosis","enrollment":1044},{"nctId":"NCT01442519","phase":"PHASE3","title":"Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"1994-01","conditions":"Bladder Cancer","enrollment":212},{"nctId":"NCT00202410","phase":"PHASE2, PHASE3","title":"Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"S. Andrea Hospital","startDate":"2001-11","conditions":"Multiple Sclerosis","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HYPERKALAEMIA"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLADDER CANCER"},{"count":1,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"},{"count":1,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":1,"reaction":"CATHETER SITE INFECTION"},{"count":1,"reaction":"CATHETER SITE SWELLING"},{"count":1,"reaction":"CEREBRAL VENTRICLE DILATATION"},{"count":1,"reaction":"CLONIC CONVULSION"},{"count":1,"reaction":"DEVICE BREAKAGE"}],"_approvalHistory":[],"publicationCount":104,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BCG vaccine (Freeze-dried)","genericName":"BCG vaccine (Freeze-dried)","companyName":"Tuberculosis Research Centre, India","companyId":"tuberculosis-research-centre-india","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCG vaccine stimulates the immune system to recognize and attack Mycobacterium tuberculosis by activating T-cell and macrophage-mediated immunity. Used for Tuberculosis prevention (primary indication), Bladder cancer (intravesical BCG therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}